SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bivalirudin for Injection in the United States as a therapeutic equivalent generic for Angiomax® for Injection (bivalirudin) approved by the U.S. Food and Drug Administration. Bivalirudin for Injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240129452514/en/

(Photo: Business Wire)

Avenacy’s injectable product contains 250 mg of bivalirudin as a lyophilized powder in a single-dose vial for reconstitution. In line with Avenacy’s mission to champion patient safety and streamline patient care, Bivalirudin for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.

Avenacy will begin shipping Bivalirudin for Injection to wholesale partners this week. The Company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.

Bivalirudin for Injection had U.S. sales of approximately $25 million for the twelve months ending in June 2023.¹

Please see link for Full Prescribing Information.

Angiomax® is a registered trademark of Sandoz, Inc.

¹Source: IQVIA

About Avenacy

Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.

Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit http://www.avenacy.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240129452514/en/